GILD is Gilead Sciences, Inc. (Healthcare). Trading at $134.36. Current dividend yield: 2.44%.
Dividend snapshot
| Annual dividend rate | $3.28 |
| Current yield | 2.44% |
| Payment frequency | Quarterly |
| Next ex-dividend date | Jun 15, 2026 |
| Most recent payment date | Mar 30, 2026 |
| Last payment amount | $0.8200 |
| 5-year dividend CAGR | 3.04% |
| 3-year dividend CAGR | 2.67% |
| Payout ratio | 43% |
| Market cap | $162.26B |
| Exchange | NMS |
Recent dividend payments
| Date | Amount / share |
|---|---|
| 2026-03-13 | $0.8200 |
| 2025-12-15 | $0.7900 |
| 2025-09-15 | $0.7900 |
| 2025-06-13 | $0.7900 |
| 2025-03-14 | $0.7900 |
| 2024-12-13 | $0.7700 |
| 2024-09-13 | $0.7700 |
| 2024-06-14 | $0.7700 |
About GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Track GILD in DiviDrip
Add GILD to your portfolio on DiviDrip to track every buy, DRIP reinvestment, and dividend payment in one place. Free, no credit card, no upsell — built by dividend investors, for dividend investors.
- Open DiviDrip — search GILD and add your shares.
- View the GILD Dividend Triangle — see Revenue × EPS × Dividend growth at a glance.
- Stock Screener — find more dividend payers like GILD.
- DiviDrip Learn — free guides on DRIP, dividend tiers, ETF comparisons.
Data refreshed 2026-05-23. Not investment advice. Yields and prices change continuously; always verify the latest numbers in the live app before buying.